HOME >> BIOLOGY >> NEWS
Toward a less expensive, more convenient treatment of Gaucher's disease

Prospects for eventual development of a less costly and more convenient treatment for Gaucher's disease have brightened with new research findings reported in the May issue of ACS Chemical Biology.

The existing treatment costs up to $750,000 annually for a single patient, continues for life, and must be given intravenously rather than by mouth. An oral treatment based on the new research could cut those costs by 100-fold.

Gaucher's (go-SHAYZ) disease is rare, but ranks as the most common lysosomal storage disorder and genetic disorder affecting Jewish people of Eastern European ancestry. Individuals with Gaucher's disease, which can be fatal, produce a defective form of GC, a critical enzyme that breaks down a fatty substance called glucosylceramide.

In the new report, scientists have confirmed experiments they reported initially in 2002 that "chemical chaperones" can partially correct the genetic defect responsible for most cases of Gaucher's disease. Like aspirin, penicillin and most other existing drugs, chemical chaperones are small molecules -- natural and synthetic substances with a low molecular weight.

Using patient-derived cell lines, researchers have extended those earlier studies to provide new insights into the defect and how chaperones correct it. The defect involves protein misfolding and prevents a key enzyme, glucocerebrosidase (GC), from reaching the location in cells where it normally functions. Jeffrey W. Kelly, Ph.D., of the Scripps Research Institute (TSRI) in La Jolla, Calif., headed the research team.

"Gaucher's disease patients can now be treated with enzyme replacement therapy," Kelly explained. "The hope is that this current strategy could be replaced with a small molecule chemical chaperone therapy wherein the cost would be reduced by at least 100-fold." Although enzyme replacement therapy is highly effective in treating Gaucher's disease, treatment often costs $100,000-$750,00
'"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-4400
American Chemical Society
24-May-2006


Page: 1 2

Related biology news :

1. Toward improved forms of a time-tested cholesterol-fighter
2. Toward more effective paleolgenetic analysis
3. Dengue and other hemorrhagic fevers: Towards a first potential treatment
4. Towards predicting late-stage radiation toxicity
5. Towards the mechanism of cell respiration
6. Towards a unified model of transcription termination
7. Towards a cheap and easy way to monitor HIV/AIDS
8. Towards targeted lung cancer treatment
9. Toward a better understanding of taste and smell impairments
10. Inexpensive, mass-produced genes at core of synthetic biology advances at UH
11. New system of wastewater treatment could reduce the size of treatment plants by half

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/1/2018)... ... August 01, 2018 , ... Clinical Training for Regenerative Medicine ... staff. , This full day course is an interactive day with lectures, demonstrations, ... staff to regenerative medicine procedures and processing techniques, and facility providing them with ...
(Date:7/31/2018)... ... ... Fiberstar, Inc. , a global leader of clean label, functional fibers ... Fiberstar added capacity, introduced new Citri-Fi® products and entered into new categories. To increase ... with Batory Foods. , “Batory Foods has an excellent track record within the ...
(Date:7/27/2018)... ... July 27, 2018 , ... ... and representatives of the Biotechnology Innovation Organization (BIO) met with U.S. Environmental ... “Proposal for a Toxic Substances Control Act (TSCA) Inventory Representation and Equivalency ...
Breaking Biology News(10 mins):
(Date:8/7/2018)... ... August 06, 2018 , ... Slone Partners, ... the placement of Dr. Paul Harney as President, North America at Prescient Healthcare ... and enhancing client satisfaction. He was also named to Prescient’s Board of Directors. ...
(Date:7/31/2018)... Calif. (PRWEB) , ... July 31, 2018 , ... ... issued a major patent that covers methods for extracting and using adipose tissue-derived ... in any mammal, including humans. While this patent covers Canada specifically, VetStem ...
(Date:7/27/2018)... WASHINGTON (PRWEB) , ... July ... ... Biobased and Renewable Products Advocacy Group (BRAG®) and representatives of the Biotechnology ... discuss the two groups’ recently-issued white paper, “Proposal for a Toxic Substances ...
(Date:7/25/2018)... ... July 25, 2018 , ... Dimitrius ... proprietary nutraceutical to combat inflammation and autoimmune disorders. , The preclinical research ... The following data was reported:, Over 70% decrease ...
Breaking Biology Technology:
Cached News: